Associate Vice Chancellor, RBHS, and Associate Director, Rutgers CINJ
NEW BRUNSWICK, New Jersey
Andrew M. Evens, DO, MBA, MSc, is the Associate Vice Chancellor for Clinical Innovation and Data Analytics, Rutgers Biomedical and Health Sciences (RBHS); Associate Director for Clinical Services at the Rutgers Cancer Institute of New Jersey; and he is Medical Director of the Oncology Service Line and Oncology Lead for the Combined Medical Group for RWJBarnabas Health (RWJBH). He works to further the mission of the State’s only NCI-designated Comprehensive Cancer Center, helping to deliver innovative, high-quality, integrated cancer care across 15 acute care hospitals and associated oncology practices throughout the State of New Jersey. He also works closely with RBHS leadership, the combined physician medical practice, and RWJBH system leadership in advancing evidence-based practices to ensure robust and dynamic clinical decision support.
Dr. Evens is a clinical expert in the field of lymphoid malignancies, with research interests including the study of novel therapeutic agents, predictive modeling, and the application of precision medicine. Nationally, he is a core member of the Hodgkin Lymphoma Working Group for the National Institutes of Health and National Cancer Institute; Vice-Chair of the Lymphoma Committee for the ECOG-ACRIN NCI research group; co-chair of the Big Ten Cancer Research Consortium lymphoma committee; a Board of Trustees member for the Leukemia & Lymphoma Society, New Jersey Chapter; and a re-elected member to the North American Scientific Advisory Board (SAB) for the Lymphoma Research Foundation. He is also a Professor of Medicine at Robert Wood Johnson Medical School.